Sirna Therapeutics

San Francisco, United States Founded: 1992 • Age: 34 yrs Acquired By Alnylam
Develops RNAi-based therapies
Request Access

About Sirna Therapeutics

Sirna Therapeutics is a company based in San Francisco (United States) founded in 1992 was acquired by Alnylam in January 2014.. Sirna Therapeutics operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.

  • Headquarter San Francisco, United States
  • Sectors
    Healthcare
    Technology
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Sirna Therapeutics Inc
Operational Areas
Healthcare → Healthcare Products & Supplies
Technology → Quantum & Emerging Technologies
Healthcare → Healthcare Products & Supplies
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
    $28.01 M (USD), Post-IPO

    Jul 07, 2005

  • Investors
    Alnylam

    & 5 more

  • Employee Count
    Employee Count
  • Acquired by
    Alnylam

    (Jan 12, 2014)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Sirna Therapeutics

  • Total Funding
  • Total Rounds 3
  • Last Round Post-IPO — $28.0M
  • First Round

    (24 Apr 2003)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2005 Amount Post-IPO - Sirna Therapeutics Valuation

investors

May, 2004 Amount Post-IPO - Sirna Therapeutics Valuation

investors

Apr, 2003 Amount Post-IPO - Sirna Therapeutics Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Sirna Therapeutics

Sirna Therapeutics has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Alnylam, Credit Suisse and Oxford Bioscience Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Early stage VC firm investing in the US and Korea
Founded Year Domain Location
Venture capital firm focused on tech sectors
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Sirna Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Sirna Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Sirna Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Sirna Therapeutics

Sirna Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
An AI-enabled platform is developed for infectious disease treatment.
domain founded_year HQ Location
Therapeutics for genetic diseases are developed through targeted interventions.
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
Gene therapies for rare diseases are developed to treat patients.
domain founded_year HQ Location
Gene therapies for rare diseases including retinal dystrophies are developed.
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Sirna Therapeutics

Frequently Asked Questions about Sirna Therapeutics

When was Sirna Therapeutics founded?

Sirna Therapeutics was founded in 1992 and raised its 1st funding round 11 years after it was founded.

Where is Sirna Therapeutics located?

Sirna Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

What does Sirna Therapeutics do?

Sirna Therapeutics is a biotechnology company that develops therapeutics based on RNA interference (RNAi) technology. The company develops small interfering RNA (siRNA) drugs. The company started a clinical trial of its siRNA-based treatment for age-related macular degeneration. The company went public in 2008. Sirna Therapeutics is a biotechnology company exploring the use of RNA interference in human disease therapy. The company was acquired by Merck Co. in 2006 for 1.1B. In 2014, Sirna was acquired by Alnylam from Merck for 175M.

Who are the top competitors of Sirna Therapeutics?

Sirna Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.

Who are Sirna Therapeutics's investors?

Sirna Therapeutics has 6 investors. Key investors include Alnylam, Credit Suisse, Oxford Bioscience Partners, Venrock, and GGV Capital.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available